Curis, Inc. (Nasdaq: CRIS) presented preliminary clinical pharmacokinetic (PK) and early biomarker data from the ongoing dose escalation stage of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE